2 Stocks Down by 25% or More This Year to Buy and Hold

Group 1: Viking Therapeutics - Viking Therapeutics is a clinical-stage biotech company focused on developing medicines for metabolic and endocrine disorders, with a notable candidate VK2735 for weight management therapy [2][6] - The market for anti-obesity drugs is rapidly growing, and Viking's VK2735 has shown strong mid-stage results compared to competitors [3][4] - The company is also developing VK2809 for metabolic dysfunction-associated steatohepatitis and VK0214 for X-linked adrenoleukodystrophy, showcasing a diverse pipeline [4][5] - Viking is exploring next-generation weight loss medicines that mimic the action of hormones amylin and calcitonin, indicating a proactive approach to innovation [5][6] - Despite recent struggles, clinical and regulatory progress could lead to substantial gains, making it an attractive investment for those willing to accept volatility [6] Group 2: PayPal - PayPal's shares have declined due to disappointing fourth-quarter results, particularly from its Braintree payment processing platform [7][8] - The company has strategically chosen to abandon unprofitable volume, which may lead to lower short-term sales but higher future profits and margins [8] - PayPal has made significant changes to its business, including the development of an advertising business that could enhance revenue by linking active accounts with businesses [9][8] - With 434 million active accounts at the end of 2024, PayPal maintains a strong brand presence and a vast network of businesses, enhancing its attractiveness to consumers [9][10] - The company's platform benefits from a network effect, which strengthens its competitive position in the fintech industry, suggesting long-term growth potential [10][11]